Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MDGL |
---|---|---|
09:32 ET | 2648 | 230.2 |
09:34 ET | 200 | 232.66 |
09:36 ET | 145 | 230.64 |
09:38 ET | 100 | 231.33 |
09:41 ET | 100 | 231.635 |
09:43 ET | 224 | 232 |
09:48 ET | 400 | 232.85 |
09:52 ET | 1696 | 233.11 |
09:56 ET | 100 | 231.47 |
09:59 ET | 340 | 232.175 |
10:01 ET | 350 | 232.28 |
10:08 ET | 232 | 231.79 |
10:10 ET | 203 | 231.125 |
10:14 ET | 100 | 231.355 |
10:15 ET | 100 | 231.41 |
10:17 ET | 618 | 230.0183 |
10:21 ET | 1300 | 230.51 |
10:24 ET | 1599 | 232.19 |
10:26 ET | 100 | 231.86 |
10:30 ET | 1100 | 232.595 |
10:32 ET | 200 | 232.45 |
10:35 ET | 100 | 232.9 |
10:39 ET | 1500 | 232.83 |
10:42 ET | 200 | 233.305 |
10:50 ET | 100 | 233.5322 |
10:51 ET | 100 | 232.9 |
10:53 ET | 100 | 232.9 |
10:57 ET | 200 | 233.33 |
11:02 ET | 100 | 232.305 |
11:15 ET | 200 | 233.48 |
11:22 ET | 200 | 233.4275 |
11:44 ET | 100 | 234.95 |
11:45 ET | 100 | 234.515 |
11:56 ET | 100 | 234.305 |
12:03 ET | 100 | 234.28 |
12:20 ET | 400 | 234.71 |
12:25 ET | 100 | 234.46 |
12:32 ET | 200 | 234.825 |
12:38 ET | 200 | 235.705 |
12:39 ET | 585 | 235.835 |
12:41 ET | 400 | 236.83 |
12:43 ET | 100 | 236.465 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Madrigal Pharmaceuticals Inc | 5.1B | -9.3x | --- |
BridgeBio Pharma Inc | 5.3B | -10.5x | --- |
Avidity Biosciences Inc | 4.7B | -14.0x | --- |
Nuvalent Inc | 5.5B | -29.3x | --- |
Immunovant Inc | 4.3B | -14.9x | --- |
Krystal Biotech Inc | 5.7B | 55.2x | --- |
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.1B |
---|---|
Revenue (TTM) | $14.6M |
Shares Outstanding | 21.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.41 |
EPS | $-25.50 |
Book Value | $20.39 |
P/E Ratio | -9.3x |
Price/Sales (TTM) | 345.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,622.65% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.